EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Elekta AB (EKTAY) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Elekta AB $0.86, price $5.09, upside -83.1%, quality 51 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · US · ADR · ISIN US28617Y1010

EA Elekta AB logo Thin data Sep 24, 2026

Elekta AB

EKTAY · US

Stretched ValuationStrong overvaluation with only moderate quality.

!Fair value $0.8600 · Strongly overvalued (−83.1%)
!Quality 51/100
!Mixed Growth (revenue 5y +3.6 %/yr)
!Loss-making · -3.1% net margin (TTM)
✓Low debt · generates free cash flow
✓4.7% dividend yield · Cash covered
!Mixed vs. peers (7/14)
!Narrow moat 22/100
!Evidence only low, so the estimate is less certain
Watch Elekta AB ADR for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$12.75 $4.23 Fair Value $0.8600 Jun 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $4.23 – $12.75 · fair‑value band $0.8600 – $1.35 · the $5.09 price screens above the $0.8600 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Elekta AB ADR in your weekly email

Every Wednesday you see whether Elekta AB ADR is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.

Show more

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers linear accelerator and radiation therapy products comprising Elekta Unity for anatomy-specific MR imaging; Elekta Evo that delivers offline and online adaptive radiation therapy; Elekta Versa HD, a brain metastases solution; Elekta Harmony; and Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs, as well as quality assurance, and treatment and motion management solutions. It also provides stereotactic radiosurgery products, such as Elekta Esprit, a gamma knife system; and Leksell GammaPlan, a treatment planning and management software, as well as Elekta ONE, an oncology software suite. In addition, the company offers brachytherapy products, including Elekta Studio, an image-guided brachytherapy solution; ImagingRing for dynamic imaging; Oncentra Brachy, a smart tool that facilitates repetitive tasks; Elekta Xoft Axxent and electronic brachytherapy systems; Elekta Geneva, an applicator for cervical cancer patients; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Venezia applicator that enables the oncologist to treat locally advanced cervical cancer. Further, it provides Leksell Vantage Stereotactic System, a neurosurgery product; Elekta Kaiku for personalized cancer care; and veterinary radiation therapy solutions. Additionally, the company offers Elekta Care support services; Elekta Care 360, which provides a range of clinical and professional services; Elekta Care Learning that offers in-person and digital training courses on radiotherapy; Elekta Care Community, a self-help center; Elekta Partner Community, an online self-service portal; and Elekta Intellimax for predictive maintenance. Elekta AB (publ) was incorporated in 1972 and is headquartered in Stockholm, Sweden.

Stock analysis

Elekta AB ADR (EKTAY) currently trades at $5.09, while our model-based Fair Value estimate is $0.8600, 83.1% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $5.22 per share, and 6 of the 14 models we run sit above the $5.09 price.

Bear case: the Earnings-Based group reads lowest at $0.4700, and 8 of the 14 models stay below the price. Evidence for this calculation is low.

Scenario range: $0.8600 (bear) to $1.35 (bull), the price of $5.09 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Elekta AB ADR reported revenue of 16.4B SEK in FY2026 versus 14.5B SEK in FY2022, a compound +3.0%/yr. Reported net income was −510M SEK in FY2026.

Key figures

Market cap $2.0B · P/S ratio 0.11 · EPS (TTM) $−0.1400 · Dividend yield 4.7% · Net margin −3.1% · Return on equity −6.5% · Return on assets (EBIT) 4.4% · Revenue (TTM) 17.6B SEK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).

What moves the price

The share trades about 25% below its 52-week high and 17% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −83%, EKTAY screens richer than that median.

Fair Value models

Bear $0.8600 Fair Value $0.8600 Bull $1.35
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF $6.16 $8.78 $12.19 81
Growth DCF $6.22 $8.51 $11.34 79
Owner Earnings $1.90 $2.71 $3.79 77
All 14 models by family
DCF Models
FCF DCF $6.16 $8.78 $12.19 81
Owner Earnings $1.90 $2.71 $3.79 77
5Y Revenue Exit $3.05 $3.82 $4.68 74
5Y EBITDA Exit $4.92 $7.28 $9.94 75
10Y Revenue Exit $4.26 $5.22 $6.30 68
10Y EBITDA Exit $5.37 $7.39 $9.92 69
Earnings-Based
EPV $0.4100 $0.4700 $0.5200 74
Multiples
EV/EBIT $1.42 $1.91 $2.40 66
EV/EBITDA $4.64 $6.21 $7.77 67
EV/Revenue $0.9900 $1.44 $1.89 53
Asset-Based
NCAV (Graham) $0.9600 $1.28 $1.92 54
Growth DCF
Growth DCF $6.22 $8.51 $11.34 79
Rev-Margin DCF $3.05 $3.94 $5.00 74
Economic Profit
ROIC Compounder $0.4100 $0.4700 $0.5200 72

Open the full fair value analysis →

Notify me when EKTAY reaches fair value

Put EKTAY on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 51/100

Of which business quality 50 · Market factors (momentum, volatility) 38

Profitability 19
Margins and returns on capital today
Quality Growth 29
Are margins and returns improving?
Cashflow 73
Earnings quality: real cash, not paper profit
Fin. Strength 26
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 34
Price trend over the last 3–12 months (market factor)
52W Momentum 30
Distance to the 52-week high (market factor)
Net Issuance 80
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 36/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−9.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.6%
Start year 2021 (pandemic). Over 10 years: +3.9% a year
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
13.8% (2021) → 2.6% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−0.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.3%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in SEK, Sweden: IMF forecast 2.0% a year to 2030, 2.9% from 2016 to 2025) that is about −2.3% a year for the price and +2.3% for the forecasts.
Forecast 2027 (sales)+6.3%
Forecast 2028 (sales)+4.2%
Projected 2029 (sales)+3.9%
Projected 2030 (sales)+3.7%
Projected 2031 (sales)+3.4%

EKTAY screens overvalued: fair value 83% below the price. Compare with Abbott Laboratories, →

Compare Elekta AB ADR with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 348 stocks

Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 51 · Above median
Fair Value upside −82.9% · Bottom 25%
Profitability
Return on assets 2.5% · Above median
Net margin (TTM) −3.1% · Below median
Operating margin (TTM) 0.0% · Below median
Growth and dividend
Revenue growth −7.6% · Bottom 25%
Dividend yield (TTM) 4.7% · Top 25%
Balance sheet
Debt / equity 0.48× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 0.28× · Cheapest 25%
P/S (TTM) 0.11× · Cheapest 25%
P/FCF 0.9× · Cheapest 25%
EV/EBITDA 1.5× · Cheapest 25%
PEG 0.25× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 9
FUTURE (revenue growth)0 · sector 31
PAST (return on equity)0 · sector 12
HEALTH (low debt)76 · sector 97
DIVIDEND (yield)0 · sector 39

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $98.83 $74.79 −24%
Medtronic plc MDT $87.09 $65.61 −25%
Stryker Corporation SYK $278.77 $306.65 +10%
Boston Scientific Corporation BSX $43.65 $48.02 +10%
Edwards Lifesciences Corporation EW $85.19 $81.94 −4%
Siemens Healthineers AG SHL €37.86 €35.19 −7%
DexCom, Inc DXCM $86.68 $95.35 +10%
GE HealthCare Technologies Inc GEHC $66.63 $70.37 +6%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥153.86 ¥169.25 +10%
Koninklijke Philips N.V PHIA €21.87 €15.23 −30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Elekta AB ADR · Fair Value
$0.8600 −83%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Elekta AB ADR Fair Value". https://www.fairvalue-calculator.com/stock/EKTAY

Frequently asked questions

Is Elekta AB (EKTAY) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.8600 versus a price of $5.09, about −83% upside (overvalued).
What is the fair value of EKTAY?
Our model-based fair value for Elekta AB ADR is $0.8600 (as of Sep 24, 2026), built from audited fundamentals. The current price: $5.09.
What is the quality score of EKTAY?
Elekta AB ADR has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Elekta AB (EKTAY)?
Our model-based price target is the fair value of $0.8600 (as of Sep 24, 2026) from 14 valuation models. Cautious scenario $0.8600, optimistic scenario $1.35. It is a calculation from audited fundamentals, not an analyst target.
What is the Elekta AB ADR stock forecast for 2026?
Our models put fair value at $0.8600, about −83% upside versus a price of $5.09 (overvalued). Cautious scenario $0.8600, optimistic scenario $1.35. The calculation is refreshed regularly with new filings.
What is the revenue of Elekta AB (EKTAY)?
Elekta AB ADR reported trailing-twelve-month revenue of about 17.6B SEK (latest available figure, as of Sep 24, 2026).
Does Elekta AB ADR pay a dividend?
Elekta AB ADR currently shows a dividend yield of about 4.74% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Elekta AB (EKTAY)?
For today's price to be fair in a discounted-cash-flow model, Elekta AB ADR would have to grow free cash flow by -0.4 % per year for five years (discount rate 11.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +3.6 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of EKTAY use?
Our models discount Elekta AB ADR at 11.1 %: a base by market capitalisation (small), damped by beta 0.95, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Elekta AB ADR that is -0.4 % per year a year over ten years, using the same discount rate (11.1 %) and the same formula as our fair value.
How much growth has Elekta AB (EKTAY) delivered so far?
Over the past 5 years revenue at Elekta AB ADR grew +3.6 % a year. The price currently implies -0.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Elekta AB (EKTAY) growing?
The median revenue growth in the sector is +5.2 % a year. That is the yardstick for the growth priced into Elekta AB ADR (-0.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Elekta AB (EKTAY)?
The free-cash-flow yield on the price is 11.72 %: that much free cash flow Elekta AB ADR produces per unit of market value. When it exceeds the discount rate of our models (11.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Elekta AB (EKTAY)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Elekta AB ADR it is $0.8600 per share (as of Sep 24, 2026), against a price of $5.09. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is Elekta AB ADR stock overvalued or undervalued in 2026?
As of Sep 24, 2026, EKTAY trades above its calculated fair value: price $5.09, fair value $0.8600, a gap of about −83% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EKTAY?
No. The price is what the market pays today ($5.09); the fair value is what the company's own numbers justify ($0.8600). For Elekta AB ADR the two are $4.23 per share apart. That gap is exactly why we show both numbers side by side.
How much is Elekta AB ADR worth?
The market values Elekta AB ADR at about $2.0B (market capitalisation, as of Sep 24, 2026). Per share that is $5.09; our models calculate a fair value of $0.8600 per share.
What do the bullish and bearish scenarios say about EKTAY?
Our models span a range for Elekta AB ADR: cautious scenario $0.8600, base $0.8600, optimistic $1.35 per share (as of Sep 24, 2026, price $5.09). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of EKTAY?
The PEG ratio of Elekta AB ADR is 0.25 (P/E divided by earnings growth, as of Sep 24, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Elekta AB (EKTAY)?
Balance-sheet figures for Elekta AB ADR (as of Sep 24, 2026): return on equity −6.5%, debt of 0.48 per unit of equity. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is EKTAY from its 52-week high?
Elekta AB ADR trades at $5.09, about 25% below its 52-week high of $6.74 and 17% above the low of $4.33 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $0.8600 is for.
Which stocks are comparable to Elekta AB ADR?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Elekta AB ADR stock attractive at the current price?
The data as of Sep 24, 2026: price $5.09, calculated fair value $0.8600 (−83%), Quality Score 51/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EKTAY calculated?
We run Elekta AB ADR through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.8600, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Elekta AB ADR itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Elekta AB (EKTAY)?
The closing price on Oct 2, 2026 was $5.09. Our model-based fair value is $0.8600, about −83% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Elekta AB ADR right now?
The price sits above even our optimistic bull case ($1.35). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (51/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of Elekta AB (EKTAY) come from?
Earnings per share at Elekta AB ADR grew +13.0 % a year from 2015 to 2026. Broken into its drivers: revenue per share +6.1 %, EBIT margin +3.7 %, tax rate +0.9 %, residual (interest, one-offs) +1.9 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Elekta AB ADR

How large is the market capitalisation of Elekta AB (EKTAY)?
The market capitalisation of Elekta AB ADR is $2.0B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Elekta AB (EKTAY)?
The price-to-sales ratio of Elekta AB ADR is 0.11 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Elekta AB (EKTAY)?
Earnings per share at Elekta AB ADR are $−0.1400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Elekta AB (EKTAY)?
The dividend yield of Elekta AB ADR is 4.7%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Elekta AB (EKTAY)?
The net margin of Elekta AB ADR is −3.1% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Elekta AB (EKTAY)?
The return on equity (ROE) of Elekta AB ADR is −6.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Elekta AB (EKTAY)?
On an EBIT basis the return on assets of Elekta AB ADR is 4.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast is revenue growing at Elekta AB (EKTAY)?
Revenue at Elekta AB ADR is growing −7.6% versus a year earlier (3y avg −1.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Elekta AB (EKTAY)?
Earnings per share at Elekta AB ADR are growing −97.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Elekta AB (EKTAY) carry?
The net debt of Elekta AB ADR is 4.1B SEK (fiscal year 2026, ≈ 1.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Elekta AB ADR in the live analysis

One click puts Elekta AB ADR on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.